Organon & Key Executives
This section highlights Organon &'s key executives, including their titles and compensation details.
Find Contacts at Organon &
(Showing 0 of )
Organon & Earnings
This section highlights Organon &'s earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
May 01, 2025
Time:
Before Market
Est. EPS:
$0.92
Status:
Unconfirmed
Last Earnings Results
Date:
February 13, 2025
EPS:
$0.90
Est. EPS:
$0.92
Revenue:
$1.59B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-13 | $0.92 | $0.90 |
| Read Transcript | Q3 | 2024 | 2024-10-31 | $0.90 | $0.87 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $1.06 | $1.12 |
| Read Transcript | Q1 | 2024 | 2024-05-02 | $0.97 | $1.22 |
| Read Transcript | Q4 | 2023 | 2024-02-15 | $0.80 | $0.88 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $1.04 | $0.87 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $0.97 | $1.31 |
| Read Transcript | Q1 | 2023 | 2023-05-04 | $1.18 | $1.08 |
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Healthcare
Drug Manufacturers - General
$15.39
Stock Price
$3.97B
Market Cap
10.00K
Employees
Jersey City, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Organon &, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $6.40B | $6.26B | $6.17B | $6.30B | $8.10B |
| Cost of Revenue | $2.69B | $2.52B | $2.29B | $2.38B | $3.35B |
| Gross Profit | $3.71B | $3.75B | $3.88B | $3.92B | $4.75B |
| Gross Profit Ratio | 58.02% | 59.80% | 62.84% | 62.20% | 58.66% |
| Research and Development Expenses | $469.00M | $528.00M | $471.00M | $443.00M | $304.00M |
| General and Administrative Expenses | $- | $1.68B | $1.45B | $1.43B | $1.47B |
| Selling and Marketing Expenses | $- | $209.00M | $255.00M | $236.00M | $198.00M |
| Selling General and Administrative Expenses | $1.76B | $1.89B | $1.70B | $1.67B | $1.67B |
| Other Expenses | $- | $- | $-15.00M | $-279.00M | $-29.00M |
| Operating Expenses | $2.23B | $2.42B | $2.17B | $2.11B | $1.97B |
| Cost and Expenses | $4.92B | $4.94B | $4.47B | $4.49B | $5.32B |
| Interest Income | $- | $- | $422.00M | $258.00M | $- |
| Interest Expense | $520.00M | $527.00M | $422.00M | $258.00M | $6.00M |
| Depreciation and Amortization | $277.00M | $236.00M | $212.00M | $195.00M | $142.00M |
| EBITDA | $1.60B | $1.44B | $1.69B | $1.81B | $2.99B |
| EBITDA Ratio | 25.05% | 22.93% | 27.37% | 28.78% | 37.13% |
| Operating Income | $1.49B | $1.33B | $1.48B | $1.62B | $2.85B |
| Operating Income Ratio | 23.21% | 21.19% | 23.94% | 25.68% | 35.19% |
| Total Other Income Expenses Net | $-679.00M | $-654.00M | $-583.00M | $-386.00M | $-95.00M |
| Income Before Tax | $807.00M | $673.00M | $1.12B | $1.53B | $2.68B |
| Income Before Tax Ratio | 12.60% | 10.75% | 18.17% | 24.25% | 33.10% |
| Income Tax Expense | $-57.00M | $-350.00M | $205.00M | $178.00M | $520.00M |
| Net Income | $864.00M | $1.02B | $917.00M | $1.35B | $2.16B |
| Net Income Ratio | 13.49% | 16.33% | 14.85% | 21.43% | 26.68% |
| EPS | $3.36 | $4.01 | $3.61 | $5.33 | $8.52 |
| EPS Diluted | $3.33 | $3.99 | $3.59 | $5.33 | $8.52 |
| Weighted Average Shares Outstanding | 257.05M | 255.24M | 254.08M | 253.55M | 253.52M |
| Weighted Average Shares Outstanding Diluted | 259.15M | 256.27M | 255.17M | 253.55M | 253.52M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.59B | $1.58B | $1.61B | $1.62B | $1.60B | $1.52B | $1.61B | $1.54B | $1.49B | $1.54B | $1.58B | $1.57B | $1.60B | $1.60B | $1.59B | $1.51B | $3.18B | $1.61B | $1.53B | $1.78B |
| Cost of Revenue | $696.00M | $659.00M | $668.00M | $665.00M | $683.00M | $612.00M | $640.00M | $580.00M | $594.00M | $551.00M | $588.00M | $561.00M | $599.00M | $609.00M | $583.00M | $591.00M | $1.81B | $535.00M | $460.00M | $538.00M |
| Gross Profit | $896.00M | $923.00M | $939.00M | $957.00M | $915.00M | $907.00M | $968.00M | $958.00M | $891.00M | $986.00M | $997.00M | $1.01B | $1.00B | $991.00M | $1.01B | $915.00M | $1.36B | $1.08B | $1.07B | $1.24B |
| Gross Profit Ratio | 56.28% | 58.30% | 58.40% | 59.00% | 57.30% | 59.70% | 60.20% | 62.30% | 60.00% | 64.20% | 62.90% | 64.20% | 62.70% | 61.90% | 63.40% | 60.80% | 42.90% | 66.83% | 69.86% | 69.78% |
| Research and Development Expenses | $130.00M | $111.00M | $116.00M | $112.00M | $134.00M | $137.00M | $128.00M | $129.00M | $142.00M | $127.00M | $106.00M | $96.00M | $189.00M | $111.00M | $76.00M | $67.00M | $154.00M | $54.00M | $51.00M | $45.00M |
| General and Administrative Expenses | $- | $- | $- | $- | $260.00M | $- | $- | $- | $215.00M | $- | $- | $- | $245.00M | $- | $- | $- | $546.00M | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $209.00M | $- | $- | $- | $255.00M | $- | $- | $- | $236.00M | $- | $- | $- | $198.00M | $- | $- | $- |
| Selling General and Administrative Expenses | $470.00M | $422.00M | $437.00M | $431.00M | $469.00M | $538.00M | $451.00M | $435.00M | $470.00M | $440.00M | $423.00M | $371.00M | $481.00M | $388.00M | $416.00M | $382.00M | $744.00M | $321.00M | $284.00M | $317.00M |
| Other Expenses | $296.00M | $- | $-6.00M | $-3.00M | $-4.00M | $-4.00M | $-1.00M | $-6.00M | $- | $-4.00M | $14.00M | $-97.00M | $-99.00M | $-102.00M | $-82.00M | $-2.00M | $-37.00M | $8.00M | $11.00M | $-11.00M |
| Operating Expenses | $896.00M | $533.00M | $553.00M | $543.00M | $603.00M | $675.00M | $579.00M | $564.00M | $612.00M | $567.00M | $529.00M | $467.00M | $670.00M | $499.00M | $492.00M | $449.00M | $898.00M | $375.00M | $335.00M | $362.00M |
| Cost and Expenses | $1.59B | $1.19B | $1.22B | $1.21B | $1.29B | $1.29B | $1.22B | $1.14B | $1.21B | $1.12B | $1.12B | $1.03B | $1.27B | $1.11B | $1.07B | $1.04B | $2.71B | $910.00M | $795.00M | $900.00M |
| Interest Income | $- | $- | $- | $- | $- | $134.00M | $132.00M | $132.00M | $119.00M | $108.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $132.00M | $126.00M | $131.00M | $131.00M | $129.00M | $134.00M | $132.00M | $132.00M | $119.00M | $108.00M | $98.00M | $97.00M | $98.00M | $98.00M | $62.00M | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $77.00M | $69.00M | $66.00M | $65.00M | $60.00M | $61.00M | $58.00M | $57.00M | $52.00M | $57.00M | $50.00M | $53.00M | $62.00M | $52.00M | $43.00M | $38.00M | $50.00M | $40.00M | $34.00M | $33.00M |
| EBITDA | $338.00M | $402.00M | $432.00M | $479.00M | $374.00M | $293.00M | $447.00M | $451.00M | $279.00M | $476.00M | $518.00M | $592.00M | $396.00M | $569.00M | $563.00M | $504.00M | $509.00M | $743.00M | $765.00M | $938.00M |
| EBITDA Ratio | 21.23% | 25.41% | 28.13% | 29.53% | 23.15% | 15.01% | 24.13% | 25.23% | 18.79% | 27.00% | 30.41% | 34.40% | 20.89% | 30.81% | 32.66% | 33.27% | 18.16% | 46.56% | 50.85% | 52.70% |
| Operating Income | $- | $390.00M | $386.00M | $414.00M | $312.00M | $232.00K | $389.00K | $331.00M | $227.00M | $358.00M | $432.00M | $486.00M | $334.00M | $394.00M | $458.00M | $466.00M | $465.00M | $703.00M | $731.00M | $880.00M |
| Operating Income Ratio | 0.00% | 24.65% | 24.02% | 25.52% | 19.52% | 0.02% | 0.02% | 21.52% | 15.29% | 23.29% | 27.26% | 31.01% | 20.82% | 24.62% | 28.71% | 30.94% | 14.64% | 43.58% | 47.90% | 49.44% |
| Total Other Income Expenses Net | $129.00M | $-183.00M | $-151.00M | $-178.00M | $-208.00M | $-152.00M | $-135.00M | $-159.00M | $-168.00M | $-137.00M | $-181.00M | $-97.00M | $-98.00M | $-128.00M | $-21.00M | $1.00M | $-12.00M | $-22.00M | $-29.00M | $-36.00M |
| Income Before Tax | $129.00M | $207.00M | $235.00M | $236.00M | $104.00M | $80.00M | $254.00M | $235.00M | $111.00M | $282.00M | $287.00M | $442.00M | $236.00M | $389.00M | $437.00M | $467.00M | $453.00M | $681.00M | $702.00M | $844.00M |
| Income Before Tax Ratio | 8.10% | 13.08% | 14.62% | 14.55% | 6.51% | 5.27% | 15.80% | 15.28% | 7.47% | 18.35% | 18.11% | 28.21% | 14.71% | 24.31% | 27.40% | 31.01% | 14.26% | 42.22% | 46.00% | 47.42% |
| Income Tax Expense | $20.00M | $-152.00M | $40.00M | $35.00M | $-442.00M | $22.00M | $12.00M | $58.00M | $3.00M | $55.00M | $53.00M | $94.00M | $34.00M | $66.00M | $6.00M | $72.00M | $173.00M | $121.00M | $116.00M | $110.00M |
| Net Income | $109.00M | $359.00M | $195.00M | $201.00M | $546.00M | $58.00M | $242.00M | $177.00M | $108.00M | $227.00M | $234.00M | $348.00M | $202.00M | $323.00M | $427.00M | $399.00M | $368.00M | $547.00M | $542.00M | $703.00M |
| Net Income Ratio | 6.85% | 22.69% | 12.13% | 12.39% | 34.17% | 3.82% | 15.05% | 11.51% | 7.27% | 14.77% | 14.76% | 22.21% | 12.59% | 20.19% | 26.77% | 26.49% | 11.58% | 33.91% | 35.52% | 39.49% |
| EPS | $0.42 | $1.39 | $0.76 | $0.79 | $2.14 | $0.23 | $0.95 | $0.70 | $0.42 | $0.89 | $0.92 | $1.37 | $0.80 | $1.27 | $1.68 | $1.58 | $1.45 | $2.16 | $2.14 | $2.78 |
| EPS Diluted | $0.42 | $1.38 | $0.75 | $0.78 | $2.13 | $0.23 | $0.95 | $0.69 | $0.42 | $0.89 | $0.92 | $1.36 | $0.79 | $1.27 | $1.68 | $1.58 | $1.45 | $2.16 | $2.14 | $2.78 |
| Weighted Average Shares Outstanding | 257.69M | 257.50M | 257.29M | 255.69M | 255.62M | 255.59M | 255.34M | 254.39M | 254.37M | 254.35M | 254.02M | 253.58M | 253.55M | 253.53M | 253.52M | 253.13M | 253.13M | 253.13M | 253.13M | 253.13M |
| Weighted Average Shares Outstanding Diluted | 259.88M | 259.76M | 258.60M | 258.36M | 256.59M | 256.35M | 255.95M | 256.17M | 255.39M | 255.07M | 255.16M | 255.05M | 254.55M | 254.17M | 253.83M | 253.13M | 253.13M | 253.13M | 253.13M | 253.13M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $675.00M | $693.00M | $706.00M | $737.00M | $500.00M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $675.00M | $693.00M | $706.00M | $737.00M | $500.00M |
| Net Receivables | $1.36B | $1.74B | $1.48B | $1.38B | $1.09B |
| Inventory | $1.32B | $1.31B | $1.00B | $915.00M | $913.00M |
| Other Current Assets | $994.00M | $756.00M | $747.00M | $726.00M | $1.55B |
| Total Current Assets | $4.35B | $4.51B | $3.93B | $3.76B | $3.43B |
| Property Plant Equipment Net | $1.17B | $1.18B | $1.02B | $973.00M | $984.00M |
| Goodwill | $4.68B | $4.60B | $4.60B | $4.60B | $4.60B |
| Intangible Assets | $1.41B | $533.00M | $649.00M | $651.00M | $503.00M |
| Goodwill and Intangible Assets | $6.09B | $5.14B | $5.25B | $5.25B | $5.11B |
| Long Term Investments | $- | $- | $- | $-4.00M | $- |
| Tax Assets | $- | $- | $19.00M | $4.00M | $- |
| Other Non-Current Assets | $1.49B | $1.23B | $735.00M | $694.00M | $910.00M |
| Total Non-Current Assets | $8.75B | $7.55B | $7.02B | $6.92B | $7.00B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $13.10B | $12.06B | $10.96B | $10.68B | $10.43B |
| Account Payables | $1.15B | $1.31B | $1.13B | $1.38B | $259.00M |
| Short Term Debt | $20.00M | $9.00M | $8.00M | $9.00M | $16.00M |
| Tax Payables | $134.00M | $206.00M | $184.00M | $185.00M | $109.00M |
| Deferred Revenue | $- | $- | $19.00M | $- | $-8.00M |
| Other Current Liabilities | $1.41B | $1.39B | $1.19B | $1.02B | $2.29B |
| Total Current Liabilities | $2.72B | $2.92B | $2.51B | $2.60B | $1.20B |
| Long Term Debt | $8.86B | $8.88B | $9.05B | $9.31B | $46.00M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-23.00M |
| Deferred Tax Liabilities Non-Current | $74.00M | $47.00M | $19.00M | $4.00M | $121.00M |
| Other Non-Current Liabilities | $977.00M | $287.00M | $261.00M | $279.00M | $1.90B |
| Total Non-Current Liabilities | $9.91B | $9.21B | $9.34B | $9.59B | $10.05B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $12.63B | $12.13B | $11.85B | $12.19B | $11.25B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M |
| Retained Earnings | $1.01B | $443.00M | $-331.00M | $-998.00M | $-219.00M |
| Accumulated Other Comprehensive Income Loss | $-649.00M | $-541.00M | $-564.00M | $-513.00M | $-604.00M |
| Other Total Stockholders Equity | $108.00M | $25.00M | $- | $- | $- |
| Total Stockholders Equity | $472.00M | $-70.00M | $-892.00M | $-1.51B | $-820.00M |
| Total Equity | $472.00M | $-70.00M | $-892.00M | $-1.51B | $-820.00M |
| Total Liabilities and Stockholders Equity | $13.10B | $12.06B | $10.96B | $10.68B | $10.43B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $13.10B | $12.06B | $10.96B | $10.68B | $10.43B |
| Total Investments | $- | $-47.00M | $- | $-4.00M | $- |
| Total Debt | $8.88B | $8.76B | $8.91B | $9.13B | $31.00M |
| Net Debt | $8.21B | $8.07B | $8.21B | $8.40B | $-469.00M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $675.00M | $763.00M | $704.00M | $575.00M | $693.00M | $414.00M | $326.00M | $459.00M | $706.00M | $499.00M | $545.00M | $694.00M | $737.00M | $1.01B | $730.00M | $141.00M | $500.00M | $-319.00M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $638.00M |
| Cash and Short Term Investments | $675.00M | $763.00M | $704.00M | $575.00M | $693.00M | $414.00M | $326.00M | $459.00M | $706.00M | $499.00M | $545.00M | $694.00M | $737.00M | $1.01B | $730.00M | $141.00M | $500.00M | $319.00M |
| Net Receivables | $1.36B | $1.73B | $1.65B | $1.56B | $1.74B | $1.66B | $1.68B | $1.47B | $1.48B | $1.45B | $1.50B | $1.35B | $1.38B | $1.51B | $1.51B | $1.01B | $1.09B | $- |
| Inventory | $1.32B | $1.38B | $1.29B | $1.26B | $1.31B | $1.19B | $1.20B | $1.12B | $1.00B | $879.00M | $950.00M | $946.00M | $915.00M | $918.00M | $871.00M | $924.00M | $913.00M | $- |
| Other Current Assets | $994.00M | $881.00M | $866.00M | $802.00M | $756.00M | $794.00M | $750.00M | $735.00M | $747.00M | $764.00M | $780.00M | $731.00M | $726.00M | $893.00M | $803.00M | $902.00M | $1.42B | $- |
| Total Current Assets | $4.35B | $4.76B | $4.51B | $4.20B | $4.51B | $4.05B | $3.96B | $3.78B | $3.93B | $3.59B | $3.77B | $3.72B | $3.76B | $4.33B | $3.91B | $2.98B | $3.43B | $319.00M |
| Property Plant Equipment Net | $1.17B | $1.20B | $1.16B | $1.18B | $1.18B | $1.10B | $1.11B | $1.05B | $1.02B | $906.00M | $952.00M | $970.00M | $973.00M | $967.00M | $976.00M | $986.00M | $984.00M | $- |
| Goodwill | $4.68B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $4.60B | $- |
| Intangible Assets | $1.41B | $763.00M | $684.00M | $718.00M | $533.00M | $561.00M | $592.00M | $621.00M | $649.00M | $670.00M | $638.00M | $665.00M | $651.00M | $683.00M | $711.00M | $482.00M | $503.00M | $- |
| Goodwill and Intangible Assets | $6.09B | $5.37B | $5.29B | $5.32B | $5.14B | $5.16B | $5.20B | $5.22B | $5.25B | $5.27B | $5.24B | $5.27B | $5.25B | $5.29B | $5.31B | $5.08B | $5.11B | $- |
| Long Term Investments | $- | $-56.00K | $-60.00K | $5.32B | $-808.00M | $- | $-32.00K | $- | $-267.00M | $- | $- | $-2.00M | $-4.00M | $-59.00M | $-71.00M | $-4.00M | $- | $- |
| Tax Assets | $- | $56.00K | $60.00K | $44.00K | $808.00M | $43.00M | $32.00K | $30.00M | $267.00M | $43.00M | $23.00M | $2.00M | $4.00M | $59.00M | $71.00M | $4.00M | $- | $- |
| Other Non-Current Assets | $1.49B | $1.43B | $1.20B | $-4.12B | $1.23B | $659.00M | $716.00M | $674.00M | $754.00M | $623.00M | $624.00M | $640.00M | $694.00M | $753.00M | $707.00M | $594.00M | $910.00M | $-319.00M |
| Total Non-Current Assets | $8.75B | $8.00B | $7.64B | $7.70B | $7.55B | $6.96B | $7.02B | $6.98B | $7.02B | $6.84B | $6.84B | $6.88B | $6.92B | $7.01B | $7.00B | $6.67B | $7.00B | $-319.00M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $13.10B | $12.75B | $12.15B | $11.89B | $12.06B | $11.01B | $10.98B | $10.76B | $10.96B | $10.44B | $10.61B | $10.60B | $10.68B | $11.34B | $10.91B | $9.64B | $10.43B | $- |
| Account Payables | $1.15B | $1.09B | $1.24B | $955.00M | $1.31B | $1.07B | $1.11B | $996.00M | $1.13B | $1.03B | $1.13B | $1.08B | $1.38B | $1.67B | $1.81B | $264.00M | $259.00M | $- |
| Short Term Debt | $20.00M | $10.00M | $9.00M | $9.00M | $9.00M | $8.00M | $8.00M | $8.00M | $8.00M | $8.00M | $9.00M | $9.00M | $9.00M | $39.00M | $39.00M | $1.52B | $1.52B | $- |
| Tax Payables | $134.00M | $230.00K | $201.00M | $196.00M | $206.00M | $161.00M | $163.00M | $192.00M | $184.00M | $217.00M | $211.00M | $202.00M | $185.00M | $335.00M | $218.00M | $288.00M | $109.00M | $- |
| Deferred Revenue | $- | $- | $201.00M | $196.00K | $- | $161.00M | $163.00K | $- | $19.00M | $43.00M | $23.00M | $- | $- | $335.00M | $218.00M | $1.05B | $-1.34B | $- |
| Other Current Liabilities | $1.41B | $1.69B | $1.30B | $1.39B | $1.39B | $1.25B | $1.10B | $1.15B | $1.19B | $1.07B | $1.05B | $1.01B | $1.02B | $1.08B | $906.00M | $803.00M | $785.00M | $- |
| Total Current Liabilities | $2.72B | $2.79B | $2.75B | $2.54B | $2.92B | $2.49B | $2.39B | $2.35B | $2.51B | $2.33B | $2.40B | $2.31B | $2.60B | $3.13B | $2.98B | $2.88B | $1.20B | $- |
| Long Term Debt | $8.86B | $8.74B | $8.65B | $8.71B | $8.88B | $8.65B | $8.72B | $8.70B | $9.05B | $8.69B | $8.88B | $9.09B | $9.31B | $9.48B | $9.54B | $- | $46.00M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $-43.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-23.00M | $- |
| Deferred Tax Liabilities Non-Current | $74.00M | $56.00M | $60.00M | $44.00M | $47.00M | $43.00M | $32.00M | $30.00M | $19.00M | $43.00M | $23.00M | $2.00M | $4.00M | $59.00M | $71.00M | $125.00M | $121.00M | $- |
| Other Non-Current Liabilities | $977.00M | $674.00M | $548.00M | $549.00M | $287.00M | $421.00M | $393.00M | $421.00M | $261.00M | $441.00M | $448.00M | $454.00M | $279.00M | $285.00M | $260.00M | $1.92B | $1.90B | $- |
| Total Non-Current Liabilities | $9.91B | $9.47B | $9.26B | $9.30B | $9.21B | $9.11B | $9.15B | $9.15B | $9.34B | $9.18B | $9.36B | $9.54B | $9.59B | $9.82B | $9.87B | $2.04B | $10.05B | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $12.63B | $12.26B | $12.01B | $11.84B | $12.13B | $11.60B | $11.53B | $11.50B | $11.85B | $11.50B | $11.75B | $11.85B | $12.19B | $12.95B | $12.84B | $4.92B | $11.25B | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $5.41B | $3.00M | $- |
| Retained Earnings | $1.01B | $975.00M | $690.00M | $573.00M | $443.00M | $-16.00M | $-25.00M | $-206.00M | $-331.00M | $-383.00M | $-551.00M | $-724.00M | $-998.00M | $-1.13B | $-1.47B | $- | $-219.00M | $- |
| Accumulated Other Comprehensive Income Loss | $-649.00M | $-571.00M | $-612.00M | $-577.00M | $-541.00M | $-576.00M | $-533.00M | $-534.00M | $-564.00M | $-686.00M | $-589.00M | $-529.00M | $-513.00M | $-493.00M | $-464.00M | $-689.00M | $-604.00M | $7.04B |
| Other Total Stockholders Equity | $108.00M | $86.00M | $63.00M | $49.00M | $25.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $472.00M | $493.00M | $144.00M | $48.00M | $-70.00M | $-589.00M | $-555.00M | $-737.00M | $-892.00M | $-1.07B | $-1.14B | $-1.25B | $-1.51B | $-1.62B | $-1.93B | $4.72B | $-820.00M | $7.04B |
| Total Equity | $472.00M | $493.00M | $144.00M | $48.00M | $-70.00M | $-589.00M | $-555.00M | $-737.00M | $-892.00M | $-1.07B | $-1.14B | $-1.25B | $-1.51B | $-1.62B | $-1.93B | $4.72B | $-820.00M | $7.04B |
| Total Liabilities and Stockholders Equity | $13.10B | $12.75B | $12.15B | $11.89B | $12.06B | $11.01B | $10.98B | $10.76B | $10.96B | $10.44B | $10.61B | $10.60B | $10.68B | $11.34B | $10.91B | $9.64B | $10.43B | $7.04B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $13.10B | $12.75B | $12.15B | $11.89B | $12.06B | $11.01B | $10.98B | $10.76B | $10.96B | $10.44B | $10.61B | $10.60B | $10.68B | $11.34B | $10.91B | $9.64B | $10.43B | $7.04B |
| Total Investments | $- | $-762.24M | $-60.00K | $5.32B | $-808.00M | $- | $-32.00K | $- | $-267.00M | $- | $- | $-2.00M | $-4.00M | $-59.00M | $-71.00M | $-4.00M | $- | $638.00M |
| Total Debt | $8.88B | $8.75B | $8.66B | $8.71B | $8.76B | $8.65B | $8.73B | $8.71B | $8.91B | $8.70B | $8.89B | $9.09B | $9.13B | $9.30B | $9.35B | $1.52B | $1.34B | $- |
| Net Debt | $8.21B | $7.99B | $7.95B | $8.14B | $8.07B | $8.24B | $8.40B | $8.25B | $8.21B | $8.20B | $8.35B | $8.40B | $8.40B | $8.29B | $8.62B | $1.38B | $839.00M | $319.00M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $864.00M | $1.02B | $917.00M | $1.35B | $2.16B |
| Depreciation and Amortization | $132.00M | $236.00M | $212.00M | $195.00M | $157.00M |
| Deferred Income Tax | $-160.00M | $-485.00M | $-18.00M | $-288.00M | $6.00M |
| Stock Based Compensation | $105.00M | $101.00M | $75.00M | $59.00M | $40.00M |
| Change in Working Capital | $- | $-155.00M | $-452.00M | $702.00M | $-197.00M |
| Accounts Receivables | $383.00M | $-212.00M | $-123.00M | $-277.00M | $159.00M |
| Inventory | $-131.00M | $-230.00M | $-220.00M | $-138.00M | $-29.00M |
| Accounts Payables | $-157.00M | $163.00M | $-237.00M | $663.00M | $27.00M |
| Other Working Capital | $- | $124.00M | $128.00M | $454.00M | $-354.00M |
| Other Non Cash Items | $-2.00M | $79.00M | $124.00M | $439.00M | $7.00M |
| Net Cash Provided by Operating Activities | $939.00M | $799.00M | $858.00M | $2.46B | $2.19B |
| Investments in Property Plant and Equipment | $-175.00M | $-259.00M | $-427.00M | $-488.00M | $-278.00M |
| Acquisitions Net | $-166.00M | $-2.00M | $-124.00M | $-185.00M | $5.00M |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-172.00M | $1.00M | $131.00M | $192.00M | $15.00M |
| Net Cash Used for Investing Activities | $-513.00M | $-260.00M | $-420.00M | $-481.00M | $-258.00M |
| Debt Repayment | $-11.00M | $-258.00M | $-108.00M | $7.85B | $1.51B |
| Common Stock Issued | $- | $- | $11.00M | $- | $- |
| Common Stock Repurchased | $- | $-17.00M | $-11.00M | $- | $- |
| Dividends Paid | $-297.00M | $-294.00M | $-290.00M | $-145.00M | $- |
| Other Financing Activities | $-60.00M | $-17.00M | $-35.00M | $-9.03B | $-3.69B |
| Net Cash Used Provided by Financing Activities | $-368.00M | $-569.00M | $-433.00M | $-1.33B | $-2.17B |
| Effect of Forex Changes on Cash | $-76.00M | $17.00M | $-36.00M | $23.00M | $-3.00M |
| Net Change in Cash | $-18.00M | $-13.00M | $-31.00M | $667.00M | $-249.00M |
| Cash at End of Period | $675.00M | $693.00M | $706.00M | $737.00M | $70.00M |
| Cash at Beginning of Period | $693.00M | $706.00M | $737.00M | $70.00M | $319.00M |
| Operating Cash Flow | $939.00M | $799.00M | $858.00M | $2.46B | $2.19B |
| Capital Expenditure | $-175.00M | $-261.00M | $-427.00M | $-488.00M | $-278.00M |
| Free Cash Flow | $764.00M | $538.00M | $431.00M | $1.97B | $1.91B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $109.00M | $359.00M | $195.00M | $201.00M | $546.00M | $58.00M | $242.00M | $177.00M | $108.00M | $227.00M | $234.00M | $348.00M | $202.00M | $323.00M | $431.00M | $395.00M | $280.00M | $560.00M | $586.00M | $734.00M |
| Depreciation and Amortization | $77.00M | $69.00M | $66.00M | $65.00M | $60.00M | $61.00M | $58.00M | $57.00M | $52.00M | $57.00M | $50.00M | $53.00M | $62.00M | $52.00M | $43.00M | $38.00M | $50.00M | $40.00M | $34.00M | $33.00M |
| Deferred Income Tax | $10.00M | $-196.00M | $21.00M | $5.00M | $-489.00M | $8.00M | $-7.00M | $3.00M | $- | $-9.00M | $-5.00M | $-4.00M | $-76.00M | $-41.00M | $-146.00M | $-25.00M | $-12.00M | $8.00M | $25.00M | $-15.00M |
| Stock Based Compensation | $26.00M | $25.00M | $28.00M | $26.00M | $27.00M | $27.00M | $25.00M | $22.00M | $23.00M | $18.00M | $19.00M | $15.00M | $15.00M | $15.00M | $18.00M | $11.00M | $22.00M | $11.00M | $11.00M | $10.00M |
| Change in Working Capital | $112.00M | $-167.00M | $-301.00M | $-223.00M | $225.00M | $90.00M | $-307.00M | $-163.00M | $55.00M | $25.00M | $-243.00M | $-289.00M | $-228.00M | $-9.00M | $65.00M | $874.00M | $40.00M | $-299.00M | $77.00M | $-15.00M |
| Accounts Receivables | $341.00M | $-87.96M | $-75.00M | $163.00M | $-27.00M | $6.00M | $-230.00M | $39.00M | $-4.00M | $6.00M | $-179.00M | $54.00M | $99.00M | $-4.00M | $-332.00M | $-40.00M | $286.00M | $-147.00M | $176.00M | $-156.00M |
| Inventory | $-31.00M | $38.90M | $-58.00M | $19.00M | $-93.00M | $-13.00M | $-86.00M | $-38.00M | $-86.00M | $-53.00M | $-95.00M | $14.00M | $-48.00M | $-92.00M | $35.00M | $-33.00M | $-30.00M | $31.00M | $-20.00M | $-10.00M |
| Accounts Payables | $58.00M | $55.78M | $293.00M | $-349.00M | $231.00M | $-42.00M | $113.00M | $-139.00M | $86.00M | $-86.00M | $61.00M | $-298.00M | $-281.00M | $-130.00M | $1.07B | $4.00M | $16.00M | $18.00M | $-4.00M | $-3.00M |
| Other Working Capital | $-256.00M | $-173.73M | $-461.00M | $-56.00M | $114.00M | $139.00M | $-104.00M | $-25.00M | $59.00M | $158.00M | $-30.00M | $-59.00M | $2.00M | $217.00M | $-708.00M | $943.00M | $-232.00M | $-201.00M | $-75.00M | $154.00M |
| Other Non Cash Items | $56.00M | $51.00M | $323.00M | $325.00M | $28.00M | $17.00M | $16.00M | $18.00M | $29.00M | $-1.00M | $96.00M | $351.00M | $72.00M | $28.00M | $128.00M | $211.00M | $50.00M | $-32.00M | $70.00M | $-81.00M |
| Net Cash Provided by Operating Activities | $390.00M | $141.00M | $332.00M | $76.00M | $397.00M | $261.00M | $27.00M | $114.00M | $267.00M | $317.00M | $151.00M | $123.00M | $47.00M | $368.00M | $539.00M | $1.50B | $430.00M | $288.00M | $803.00M | $666.00M |
| Investments in Property Plant and Equipment | $-132.00M | $92.88M | $-47.00M | $-46.00M | $-81.00M | $-55.00M | $-71.00M | $-54.00M | $-65.00M | $-215.00M | $-84.00M | $-63.00M | $-138.00M | $-253.00M | $-59.00M | $-38.00M | $-144.00M | $-47.00M | $-47.00M | $-40.00M |
| Acquisitions Net | $- | $48.93M | $1.00M | $-50.00M | $-2.00M | $- | $1.00M | $- | $-55.00M | $2.00M | $-69.00M | $- | $-187.00M | $192.00M | $-190.00M | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-164.00M | $-24.00K | $- | $-50.00M | $2.00M | $- | $1.00M | $-8.00M | $59.00M | $-158.00M | $70.00M | $-30.00M | $5.00M | $192.00M | $-190.00M | $- | $26.00M | $-3.00M | $6.00M | $-9.00M |
| Net Cash Used for Investing Activities | $-296.00M | $141.78M | $-46.00M | $-96.00M | $-81.00M | $-55.00M | $-70.00M | $-54.00M | $-61.00M | $-213.00M | $-83.00M | $-63.00M | $-133.00M | $-61.00M | $-249.00M | $-38.00M | $-118.00M | $-50.00M | $-41.00M | $-49.00M |
| Debt Repayment | $-2.00M | $-2.00M | $-41.00M | $-2.00M | $-2.00M | $-2.00M | $-2.00M | $-252.00M | $-2.00M | $- | $-104.00M | $-2.00M | $-102.00M | $-10.00M | $- | $-566.00M | $1.17B | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $-15.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $16.00M | $-14.00M | $-2.00M | $-2.00M | $-2.00M | $-12.00M | $-1.00M | $- | $-3.00M | $-8.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $-74.00M | $-74.00M | $-79.00M | $-70.00M | $-73.00M | $-74.00M | $-74.00M | $-73.00M | $-73.00M | $-74.00M | $-72.00M | $-71.00M | $-71.00M | $-74.00M | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-6.00M | $-2.00M | $-14.00M | $-2.00M | $-2.00M | $-2.00M | $-12.00M | $-1.00M | $-7.00M | $-3.00M | $-7.00M | $-18.00M | $-14.00M | $66.00M | $233.00M | $-795.00M | $-1.84B | $-303.00M | $-577.00M | $-618.00M |
| Net Cash Used Provided by Financing Activities | $-82.00M | $-78.00M | $-134.00M | $-74.00M | $-77.00M | $-78.00M | $-88.00M | $-326.00M | $-82.00M | $-77.00M | $-183.00M | $-91.00M | $-187.00M | $-18.00M | $233.00M | $-1.36B | $-677.00M | $-303.00M | $-577.00M | $-618.00M |
| Effect of Forex Changes on Cash | $-100.00M | $71.00M | $-23.00M | $-24.00M | $40.00M | $-40.00M | $-2.00M | $19.00M | $83.00M | $-73.00M | $-34.00M | $-12.00M | $2.00M | $-11.00M | $46.00M | $-14.00M | $54.00M | $2.00M | $-61.00M | $2.00M |
| Net Change in Cash | $-88.00M | $59.00M | $129.00M | $-118.00M | $279.00M | $88.00M | $-133.00M | $-247.00M | $207.00M | $-46.00M | $-149.00M | $-43.00M | $-271.00M | $278.00M | $589.00M | $71.00M | $-311.00M | $-507.00M | $-196.00M | $1.00M |
| Cash at End of Period | $675.00M | $763.00M | $704.00M | $575.00M | $693.00M | $414.00M | $326.00M | $459.00M | $706.00M | $499.00M | $545.00M | $694.00M | $737.00M | $1.01B | $730.00M | $141.00M | $70.00M | $-63.00M | $124.00M | $320.00M |
| Cash at Beginning of Period | $763.00M | $704.00M | $575.00M | $693.00M | $414.00M | $326.00M | $459.00M | $706.00M | $499.00M | $545.00M | $694.00M | $737.00M | $1.01B | $730.00M | $141.00M | $70.00M | $381.00M | $444.00M | $320.00M | $319.00M |
| Operating Cash Flow | $390.00M | $141.00M | $332.00M | $76.00M | $397.00M | $261.00M | $27.00M | $114.00M | $267.00M | $317.00M | $151.00M | $123.00M | $47.00M | $368.00M | $539.00M | $1.50B | $430.00M | $288.00M | $803.00M | $666.00M |
| Capital Expenditure | $-132.00M | $-76.00M | $-47.00M | $-46.00M | $-81.00M | $-55.00M | $-71.00M | $-54.00M | $-65.00M | $-215.00M | $-84.00M | $-63.00M | $-138.00M | $-253.00M | $-59.00M | $-38.00M | $-144.00M | $-47.00M | $-47.00M | $-40.00M |
| Free Cash Flow | $258.00M | $65.00M | $285.00M | $30.00M | $316.00M | $206.00M | $-44.00M | $60.00M | $202.00M | $102.00M | $67.00M | $60.00M | $-91.00M | $115.00M | $480.00M | $1.47B | $286.00M | $241.00M | $756.00M | $626.00M |
Organon & Dividends
Explore Organon &'s dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
7.74%
Dividend Payout Ratio
34.38%
Dividend Paid & Capex Coverage Ratio
1.99x
Organon & Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.28 | $0.28 | February 24, 2025 | February 24, 2025 | March 13, 2025 | February 13, 2025 |
| $0.28 | $0.28 | November 12, 2024 | November 12, 2024 | December 12, 2024 | October 31, 2024 |
| $0.28 | $0.28 | August 16, 2024 | August 16, 2024 | September 12, 2024 | August 06, 2024 |
| $0.28 | $0.28 | May 10, 2024 | May 13, 2024 | June 13, 2024 | May 02, 2024 |
| $0.28 | $0.28 | February 23, 2024 | February 26, 2024 | March 14, 2024 | February 15, 2024 |
| $0.28 | $0.28 | November 10, 2023 | November 13, 2023 | December 14, 2023 | November 02, 2023 |
| $0.28 | $0.28 | August 17, 2023 | August 18, 2023 | September 14, 2023 | August 08, 2023 |
| $0.28 | $0.28 | May 12, 2023 | May 15, 2023 | June 15, 2023 | May 04, 2023 |
| $0.28 | $0.28 | February 24, 2023 | February 27, 2023 | March 16, 2023 | February 16, 2023 |
| $0.28 | $0.28 | November 10, 2022 | November 14, 2022 | December 15, 2022 | November 03, 2022 |
| $0.28 | $0.28 | August 12, 2022 | August 15, 2022 | September 15, 2022 | August 04, 2022 |
| $0.28 | $0.28 | May 13, 2022 | May 16, 2022 | June 16, 2022 | May 05, 2022 |
| $0.28 | $0.28 | February 25, 2022 | February 28, 2022 | March 17, 2022 | February 17, 2022 |
| $0.28 | $0.28 | November 19, 2021 | November 22, 2021 | December 16, 2021 | November 11, 2021 |
| $0.28 | $0.28 | August 20, 2021 | August 23, 2021 | September 13, 2021 | August 12, 2021 |
Organon & News
Read the latest news about Organon &, including recent articles, headlines, and updates.
Why Organon Is A Top Pick For Income Investors
In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector.
New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA® (tapinarof) cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings demonstrate that AD disease activity remained mild in patients who had achieved treatment success and subsequently.
High-Yield Healthcare: 3 Stocks With Strong Dividends
When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income.
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today.
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield.
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)
Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team.
Organon price target raised to $20 from $19 at Goldman Sachs
Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment of atopic dermatitis, or AD, in adults and pediatric patients 2 years of age and older. VTAMA's AD approval addresses multiple unmet needs in the atopic dermatitis market previously demonstrated by their Phase 3 results, though the firm expects successful launch will require a heightened level of investment in sales/marketing support given the primary care dimensions of the AD market, the analyst tells investors in a research note.
Organon: 7% Yield, 4x P/E, Big Upside Potential
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas.
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for OGN.